Programs & products

Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene’s...

Encouraging interim efficacy data in non-Hodgkin’s lymphoma (“NHL”) reported at the ESMO meeting in Berlin; complete response rate above current standard of care for the first set of patients...

Over a three-year period, Inserm Transfert will make available to Innate Pharma information on early-stage antibody targets discovered within Inserm’s academic research laboratories, for the purpose...

Approval by the French regulatory authorities of a first Phase IIa clinical trial with IPH 2101 in patients suffering from Multiple Myeloma, a severe haematological cancer Conducted in France, this...

The primary endpoint of the trial was met This is the first proof of concept in patients of an anti-viral effect of γδ T cell activation Innate Pharma intends to develop further its program in this...

IPH 2101 was very well tolerated at all tested doses; the pharmacodynamic endpoint was met First Phase II trial with IPH 2101 used as a single agent in multiple myeloma to begin in 2009 Available on...

Innate Pharma S.A., a biopharmaceutical company specialized in cancer immuno- therapeutics, today announced the achievement of the first milestone in their collaboration with Novo Nordisk A/S in...

Innate Pharma SA announced today the entry into regulatory pre-clinical development of IPH 2201, a novel monoclonal antibody targeting NK (Natural Killer) cells. On this occasion, the Company updated...

Innate Pharma SA anounces that it has received approval from the French authorities to start an exploratory Phase II clinical trial in chronic myeloid leukemia ("CML") with IPH 1101.